SCYX
SCYNEXIS, Inc.
There isn't enough reported data to score SCYX yet.
UNH
UnitedHealth Group Incorporated
UNH's fundamentals are mixed: free cash flow grew 31%, but earnings per share fell 8.5%. At 23x earnings, it's trading right at its usual valuation. Analysts expect strong earnings growth, though they disagree widely on how much.
SCYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
SCYX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
SCYX PE Valuation
SCYX has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
SCYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SCYX's losses to grow, with revenue declining.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
SCYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$2.64 |
| Q2 2026 | -$2.09 | +$1.11 |
| Q1 2026 | -$3.84 | +$0.64 |
| Q4 2025 | -$1.36 | +$2.16 |
| Q3 2025 | -$4.08 | +$1.28 |
| Q2 2025 | -$3.20 | +$2.00 |
| Q1 2025 | -$4.48 | -127% |
| Q4 2024 | -$3.52 | -132% |
SCYX is still losing money, but far less than before: $1.44 per share over the past year, against $76.62 at its worst in late 2019.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over SCYX on earnings quality, reporting a profit while its opponent remains loss making.
SCYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $235K | -83% |
| Q4 2025 | $18.6M | +1808% |
| Q3 2025 | $334K | -49% |
| Q2 2025 | $1.4M | +85% |
| Q1 2025 | $257K | -81% |
| Q4 2024 | $977K | -83% |
| Q3 2024 | $660K | -63% |
| Q2 2024 | $736K | -99% |
SCYX's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3309% | -2608 points |
| Q4 2025 | 56% | +881 points |
| Q3 2025 | -2516% | -953 points |
| Q2 2025 | -701% | +554 points |
| Q1 2025 | -3350% | -2658 points |
| Q4 2024 | -824% | -426 points |
| Q3 2024 | -1564% | -990 points |
| Q2 2024 | -1255% | -1344 points |
SCYX's operating margin was −3309% last quarter, up 42 points from the same quarter a year ago.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over SCYX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over SCYX on profitability, with a higher operating margin.
SCYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.5M | +$1.3M |
| Q2 2026 | -$14.9M | -$7.4M |
| Q1 2026 | -$8.1M | -$636K |
| Q4 2025 | $18.4M | +$28.3M |
| Q3 2025 | -$8.7M | -1240% |
| Q2 2025 | -$7.5M | +$3.4M |
| Q1 2025 | -$7.5M | -$3.5M |
| Q4 2024 | -$9.9M | -$2.2M |
SCYX has burned cash in almost every quarter: −$12M over the past year, against −$34M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over SCYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
SCYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +18.8K shares |
| 1 year | +90% | +5.6M shares |
| 3 years | +90% | +5.6M shares |
| 5 years | +257% | +8.5M shares |
SCYX has 12M diluted shares, up 90% from a year ago.
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over SCYX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
SCYX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.6x | Net Cash |
| Q2 2023 | -0.9x | Net Cash |
SCYX has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
SCYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.2 | Neutral |
| Stochastic | 6.3 | Oversold |
SCYX's weekly RSI is 36 (neutral) and its Stochastic is 6 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
SCYX PE vs Healthcare Sector
| Metric | SCYX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCYX has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
SCYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.96 | 16% below |
| 20 week MA | $4.44 | 25% below |
| 50 week MA | $5.40 | 38% below |
| 100 week MA | $6.29 | 47% below |
| 200 week MA | $11.4 | 71% below |
SCYX is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over SCYX on trend strength, trading above more of its moving averages.
SCYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $69.8 | $57.1 | -18% |
| 2021 | $57.1 | $54.0 | -5.5% |
| 2022 | $54.0 | $12.5 | -77% |
| 2023 | $12.5 | $17.8 | +43% |
| 2024 | $17.8 | $7.99 | -55% |
| 2025 | $7.99 | $4.70 | -41% |
| 2026 YTD | $4.70 | $3.33 | -29% |
SCYX has finished lower in five of the last six years. It's down 29% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over SCYX on returns for 2026, with the stronger performance.